HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer

BACKGROUND: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is a particularly aggressive form of the disease, and ultimately progresses in patients with metastases on standard therapies. Anthracyclines, such as doxorubicin, are an effective treatment for HER2-positive breast c...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Kathy, Cortes, Javier, Hurvitz, Sara A., Krop, Ian E., Tripathy, Debu, Verma, Sunil, Riahi, Kaveh, Reynolds, Joseph G., Wickham, Thomas J., Molnar, Istvan, Yardley, Denise A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4893300/
https://www.ncbi.nlm.nih.gov/pubmed/27259714
http://dx.doi.org/10.1186/s12885-016-2385-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4893300/
https://www.ncbi.nlm.nih.gov/pubmed/27259714
http://dx.doi.org/10.1186/s12885-016-2385-z

Ejemplares similares